Coulter Pharmaceutical is developing Bexxar, a new drug therapy to treat non-Hodgkin’s lymphoma, the second most fatal cancer. Most people afflicted with this disease have a maximum of seven years to live. In clinical trials, 71 percent of patients using Bexxar have had their cancer go into complete remission. Dramatic black-and-white portraits and personal testimonials convey the drama of anguish, recovery, and transformation many of these patients have experienced. The small quote next to the date on the cover reads, “I was supposed to die today.” After turning the cover, the reader sees a paragraph explaining the powerful benefits of Bexxar and how it saved this patient’s life.